For instance, a team led by Mingyue Zheng at SIOPA, Chinese Academy of Sciences, designed a novel DDR1 inhibitor that exhibited favorable oral therapeutic effects in DSS-induced colitis models in mice and effectively reduced inflammation [4]. This evidence concerns the gene DDR1 and colitis.